Med BioGene Inc.
TSX VENTURE : MBI

Med BioGene Inc.

June 16, 2008 08:30 ET

Med BioGene Expands Lymphoma Collaboration; Becomes Founding Corporate Collaborator of Translational Working Group in Hematologic Malignancies

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 16, 2008) - Med BioGene Inc. (TSX VENTURE:MBI), a life science company focused on the development and commercialization of genomic-based diagnostic and screening tests for cancer and cardiovascular disease, is pleased to announce that it has expanded its lymphoma collaboration with Duke University Medical Center to include Northwestern University, Indiana University and the University of Hong Kong. Discussions are currently underway with other leading universities who are expected to join the Working Group.

The expansion was facilitated through the establishment by Duke University of the Translational Working Group in Hematologic Malignancies. The first project of the Working Group, of which MBI is the corporate collaborator, is to develop genomic-based diagnostic tests for lymphoma, including the development of MBI's LymphExpress Dx™.

The principal investigators of the members of the Working Group are as follows:



Duke University Sandeep S. Dave, M.D.
Durham, NC (Lead Principal Investigator)

Northwestern University
Chicago, IL Leo I. Gordon, M.D.

Indiana University
Indianapolis, IN Magdalena Czader, M.D., Ph.D.

University of Hong Kong Gopesh Srivastava, Ph.D.


"We are very pleased to have established the Translational Working Group in Hematologic Malignancies, an open-ended collaboration of some of the best researchers and institutions focused on the diagnosis and treatment of lymphomas. We look forward to working closely with members of the Working Group and Med BioGene to develop genomic-based diagnostic tests for lymphoma designed to improve the accuracy of standard tests in pathology," noted Dr. Sandeep S. Dave of Duke University.

Erinn B. Broshko, Chief Executive Officer of MBI, stated "The expansion of our lymphoma collaboration is a major milestone in the development of LymphExpress Dx™ as it provides a significant base of expertise in all required areas and patient samples for analysis. We are very excited to be working with such an esteemed group of researchers and clinicians who are thought leaders in this space."

About Lymphoma

Lymphoma is the fifth most common cancer in the United States, afflicting approximately 74,000, and killing approximately 20,500 people each year. Lymphoma is a general term for a group of cancers that originate in the lymphatic system and is comprised of more than 42 disease subtypes. Lymphoma is divided into two major categories: Non-Hodgkin lymphoma, representing 88% of all lymphomas, and Hodgkin lymphoma, representing approximately 12% of all lymphomas. 85% of Non-Hodgkin lymphomas arise from B-cell malignancies and represent the most lethal lymphoma subtypes. Currently, approximately 40% of persons diagnosed with B-cell Non-Hodgkin lymphoma will die within five years.

Diagnosis and treatment of patients with lymphoma costs approximately $4.6 billion per year in the United States alone, with an average per patient expenditure of $21,500 in the first year after diagnosis. Accurate diagnosis of lymphoma is essential for determining prognosis and the best treatment options, but this presents a clinical challenge as pathologists may disagree regarding diagnosis of certain subtypes in as many as 47% of the cases. The experience and skill of the pathologist is of particular importance for accurate diagnoses. Conventional diagnosis can be time consuming and requires the interpretation of results from a battery of complex tests to render a diagnosis of the particular lymphoma subtype. Molecular diagnostic tools, such as LymphExpress Dx™ are expected to simplify and expedite the process while providing more accurate diagnoses.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer and cardiovascular disease. MBI develops these tests by identifying the genes, known as "biomarkers", which indicate the presence of disease. The development of these tests is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. MBI's forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information